社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
Tinktink
IP属地：未知
+关注
帖子 · 96
帖子 · 96
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
Tinktink
Tinktink
·
2021-12-11
Great
非常抱歉，此主贴已删除
看
2,201
回复
1
点赞
7
编组 21备份 2
分享
举报
Tinktink
Tinktink
·
2021-12-02
Thanks
Weibo plans to price HK listing at HK$272.80 per share<blockquote>微博计划香港上市定价为每股272.80港元</blockquote>
Weibo plans to price HK listing at HK$272.80 per share, according to IFR.
Weibo plans to price HK listing at HK$272.80 per share<blockquote>微博计划香港上市定价为每股272.80港元</blockquote>
看
2,430
回复
评论
点赞
4
编组 21备份 2
分享
举报
Tinktink
Tinktink
·
2021-11-29
Thanks
Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week<blockquote>Moderna、辉瑞和Novavax是本周必须持有的股票</blockquote>
The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday
Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week<blockquote>Moderna、辉瑞和Novavax是本周必须持有的股票</blockquote>
看
2,358
回复
评论
点赞
4
编组 21备份 2
分享
举报
Tinktink
Tinktink
·
2021-11-29
Thankd
非常抱歉，此主贴已删除
看
2,777
回复
2
点赞
3
编组 21备份 2
分享
举报
Tinktink
Tinktink
·
2021-11-22
Great
非常抱歉，此主贴已删除
看
2,122
回复
评论
点赞
5
编组 21备份 2
分享
举报
Tinktink
Tinktink
·
2021-11-18
Thanks
Life sciences software startup Benchling files for U.S. listing -sources<blockquote>生命科学软件初创公司正在为美国上市做准备——消息人士</blockquote>
Benchling, which develops software tools for scientists and pharmaceutical research organizations, h
Life sciences software startup Benchling files for U.S. listing -sources<blockquote>生命科学软件初创公司正在为美国上市做准备——消息人士</blockquote>
看
1,876
回复
评论
点赞
4
编组 21备份 2
分享
举报
Tinktink
Tinktink
·
2021-11-17
Great
Apple Could Smash Its iPhone Holiday Sales Record. What That Means for the Stock.<blockquote>苹果可能会打破iPhone假日销售记录。这对股票意味着什么。</blockquote>
Apple is on track to break its previous record for iPhone sales over the holiday period, according t
Apple Could Smash Its iPhone Holiday Sales Record. What That Means for the Stock.<blockquote>苹果可能会打破iPhone假日销售记录。这对股票意味着什么。</blockquote>
看
2,570
回复
1
点赞
5
编组 21备份 2
分享
举报
Tinktink
Tinktink
·
2021-11-15
Thanks
7 Earnings Reports to Watch Next Week<blockquote>下周值得关注的7份财报</blockquote>
A parade of retailers report earnings as their share prices remain buoyant Source: Shutterstock Reta
7 Earnings Reports to Watch Next Week<blockquote>下周值得关注的7份财报</blockquote>
看
2,166
回复
1
点赞
7
编组 21备份 2
分享
举报
Tinktink
Tinktink
·
2021-11-10
Thanks
非常抱歉，此主贴已删除
看
2,249
回复
评论
点赞
3
编组 21备份 2
分享
举报
Tinktink
Tinktink
·
2021-10-30
Nice
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought<blockquote>凯西·伍德(Cathie Wood)逢低买入：她刚刚买入的3只股票</blockquote>
Key Points ARK Invest added to its Twilio, Teladoc Health, and Robinhood positions on Thursday. Twi
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought<blockquote>凯西·伍德(Cathie Wood)逢低买入：她刚刚买入的3只股票</blockquote>
看
1,784
回复
评论
点赞
6
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3583431682924843","uuid":"3583431682924843","gmtCreate":1620344350508,"gmtModify":1620344350508,"name":"Tinktink","pinyin":"tinktink","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":9,"headSize":289,"tweetSize":96,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.79%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.03%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":605438429,"gmtCreate":1639209954076,"gmtModify":1639209984500,"author":{"id":"3583431682924843","authorId":"3583431682924843","name":"Tinktink","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583431682924843","authorIdStr":"3583431682924843"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605438429","repostId":"2190675480","repostType":4,"isVote":1,"tweetType":1,"viewCount":2201,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603508838,"gmtCreate":1638420740919,"gmtModify":1638420741168,"author":{"id":"3583431682924843","authorId":"3583431682924843","name":"Tinktink","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583431682924843","authorIdStr":"3583431682924843"},"themes":[],"htmlText":"Thanks ","listText":"Thanks ","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603508838","repostId":"1171217212","repostType":4,"repost":{"id":"1171217212","kind":"news","pubTimestamp":1638416856,"share":"https://www.laohu8.com/m/news/1171217212?lang=zh_CN&edition=full","pubTime":"2021-12-02 11:47","market":"us","language":"en","title":"Weibo plans to price HK listing at HK$272.80 per share<blockquote>微博计划香港上市定价为每股272.80港元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1171217212","media":"IFR","summary":"Weibo plans to price HK listing at HK$272.80 per share, according to IFR.","content":"<p>Weibo plans to price HK listing at HK$272.80 per share, according to IFR.</p><p><blockquote>根据IFR的数据，微博计划在香港上市的定价为每股272.80港元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Weibo plans to price HK listing at HK$272.80 per share<blockquote>微博计划香港上市定价为每股272.80港元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWeibo plans to price HK listing at HK$272.80 per share<blockquote>微博计划香港上市定价为每股272.80港元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">IFR</strong><span class=\"h-time small\">2021-12-02 11:47</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Weibo plans to price HK listing at HK$272.80 per share, according to IFR.</p><p><blockquote>根据IFR的数据，微博计划在香港上市的定价为每股272.80港元。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.ifre.com/story/3164593/weibo-plans-to-price-hk-listing-at-hk27280-per-share-rnhybgnjwr\">IFR</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09898":"微博-SW","WB":"微博"},"source_url":"https://www.ifre.com/story/3164593/weibo-plans-to-price-hk-listing-at-hk27280-per-share-rnhybgnjwr","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171217212","content_text":"Weibo plans to price HK listing at HK$272.80 per share, according to IFR.","news_type":1,"symbols_score_info":{"09898":0.9,"WB":0.9}},"isVote":1,"tweetType":1,"viewCount":2430,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600593692,"gmtCreate":1638167950260,"gmtModify":1638167950360,"author":{"id":"3583431682924843","authorId":"3583431682924843","name":"Tinktink","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583431682924843","authorIdStr":"3583431682924843"},"themes":[],"htmlText":"Thanks ","listText":"Thanks ","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600593692","repostId":"1119853738","repostType":4,"repost":{"id":"1119853738","kind":"news","pubTimestamp":1638153494,"share":"https://www.laohu8.com/m/news/1119853738?lang=zh_CN&edition=full","pubTime":"2021-11-29 10:38","market":"us","language":"en","title":"Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week<blockquote>Moderna、辉瑞和Novavax是本周必须持有的股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1119853738","media":"Motley Fool","summary":"The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday","content":"<p>The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might significantly reduce the effectiveness of first-generation COVID-19 vaccines.</p><p><blockquote>上周五，新出现的奥密克戎冠状病毒变种震惊了美国股市。奥密克戎让世界感到紧张，因为其独特的突变组合可能会显着降低第一代COVID-19疫苗的有效性。</blockquote></p><p> While there simply isn't enough data to draw any firm conclusions about the seriousness of the omicron variant yet, politicians across the world were quick to react by imposing travel bans and restrictions on several African nations over the weekend. These rapid-fire travel restrictions make it abundantly clear that the global pandemic -- and its effects on the world economy -- are far from over.</p><p><blockquote>虽然还没有足够的数据对奥密克戎变种的严重性得出任何明确的结论，但世界各地的政界人士很快做出反应，周末对几个非洲国家实施了旅行禁令和限制。这些快速的旅行限制非常清楚地表明，全球疫情及其对世界经济的影响远未结束。</blockquote></p><p> How should investors protect their portfolios from this latest threat to global supply chains, international travel, and public health? The answer appears to be simple enough: vaccine stocks. On Black Friday, shares of the top COVID-19 vaccine developers <b>Moderna</b>(NASDAQ:MRNA),<b>Pfizer</b>(NYSE:PFE), and <b>Novavax</b>(NASDAQ:NVAX) all vaulted higher. Here's why these threebiopharmaceutical stocksought to continue to their march northward next week and beyond.</p><p><blockquote>投资者应该如何保护他们的投资组合免受全球供应链、国际旅行和公共卫生的最新威胁？答案似乎很简单：疫苗库存。黑色星期五，顶级COVID-19疫苗开发商的股票<b>现代</b>（纳斯达克：MRNA），<b>辉瑞</b>（纽约证券交易所代码：PFE），以及<b>Novavax</b>（纳斯达克：NVAX）全部走高。这就是为什么这三只生物制药股寻求在下周及以后继续北上。</blockquote></p><p> The pandemic's latest twist makes these three stocks screaming buys</p><p><blockquote>疫情的最新转折让这三只股票尖叫买入</blockquote></p><p> Moderna, Pfizer, and Novavax all enjoyed a sizable jump in their share prices during the holiday-shortened trading session on Friday thanks to their quick reaction to the omicron variant. Specifically, Moderna announced that it is working on an omicron-specific vaccine, as well a unique booster shot regimen, based on its currently authorized COVID-19 vaccine, that may provide a higher level of immune protection against this new variant.</p><p><blockquote>由于对奥密克戎变种的快速反应，Moderna、辉瑞和Novavax的股价在周五假期缩短的交易时段均大幅上涨。具体来说，Moderna宣布，它正在研究一种奥密克戎特异性疫苗，以及一种基于其目前授权的COVID-19疫苗的独特加强注射方案，这可能会针对这种新变种提供更高水平的免疫保护。</blockquote></p><p> Pfizer, for its part, said that its <b>BioNTech</b>-partnered COVID-19 vaccine can easily be tailored to the omicron variant and be ready for use within 100-days -- that is, if the original version of its vaccine fails to provide adequate protection. Novavax also provided an update on its omicron vaccine strategy last Friday, with the biotech saying that it plans on having an omicron-specific shot ready for testing and manufacturing within the next few weeks.</p><p><blockquote>辉瑞则表示，其<b>BioNTech</b>-合作的COVID-19疫苗可以很容易地适应奥密克戎变种，并在100天内准备好使用——也就是说，如果其疫苗的原始版本无法提供足够的保护。Novavax上周五还提供了其奥密克戎疫苗战略的最新情况，该生物技术公司表示，计划在未来几周内准备好一种针对奥密克戎的疫苗进行测试和生产。</blockquote></p><p> Why are these omicron-tailored vaccines a huge positive for their developers? The messenger RNA (mRNA) vaccines from Moderna and Pfizer/BioNTech both appeared to be on the back end of the commercial shelf lives prior to this news. As a result, Moderna's stock was in the midst of notable downward trend earlier this month. The sudden need for more potent booster shots and a potential variant-specific vaccine should keep Moderna's top line headed in the right direction in 2022, which ought to light a fire underneath the biotech's shares for the remainder of the year.</p><p><blockquote>为什么这些奥密克戎定制的疫苗对其开发者来说是一个巨大的积极因素？在这一消息发布之前，Moderna和辉瑞/BioNTech的信使RNA(mRNA)疫苗似乎都处于商业保质期的后端。因此，Moderna的股价本月早些时候出现了明显的下跌趋势。对更有效的加强注射和潜在的变异特异性疫苗的突然需求应该会使Moderna的营收在2022年朝着正确的方向发展，这应该会在今年剩余时间里点燃该生物技术公司的股价。</blockquote></p><p> While Pfizer's equity hasn't skipped a beat of late because of its oral coronavirus pill, the pharma giant now stands to possibly benefit from another year of exceptionally strong COVID-19 vaccine sales. Pfizer's stock, in turn, will probably continue to print ever-increasing record highs heading into 2022.</p><p><blockquote>虽然辉瑞的股价最近并没有因为其口服冠状病毒药物而下跌，但这家制药巨头现在可能会受益于又一年异常强劲的COVID-19疫苗销售。反过来，辉瑞的股价可能会在2022年继续创下历史新高。</blockquote></p><p> On the Novavax side of ledger, the biotech's shares are currently down by a whopping 31% from their 52-week highs. The vaccine specialist's shares have dipped in the back half of 2021 in response to manufacturing issues, regulatory delays, and a growing concern among investors that the company may have simply missed the boat.</p><p><blockquote>在ledger的Novavax方面，该生物技术公司的股价目前较52周高点下跌了31%。由于制造问题、监管延误以及投资者越来越担心该公司可能只是错过了机会，这家疫苗专家的股价在2021年下半年下跌。</blockquote></p><p> What's important to understand is that Novavax's COVID-19 vaccine is protein-based, which may appeal to a broad range of folks hesitant about cutting-edge mRNA vaccines. This new variant, therefore, ought to keep this latent demand for Novavax's alternative jab on the high side, as the company slowly completes the regulatory process in the all-important U.S. market.</p><p><blockquote>重要的是要了解Novavax的COVID-19疫苗是基于蛋白质的，这可能会吸引许多对尖端mRNA疫苗犹豫不决的人。因此，随着Novavax在非常重要的美国市场慢慢完成监管程序，这种新变种应该会保持对Novavax替代疫苗的潜在需求偏高。</blockquote></p><p> In short, Moderna, Pfizer, and Novavax are all poised to benefit in a big way from their unique vaccine development capabilities, making their stocks exceedingly strong buys this week.</p><p><blockquote>简而言之，Moderna、辉瑞和Novavax都有望从其独特的疫苗开发能力中受益匪浅，这使得它们的股票本周受到了极其强劲的买入。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week<blockquote>Moderna、辉瑞和Novavax是本周必须持有的股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, Pfizer, and Novavax Are Must-Own Stocks This Week<blockquote>Moderna、辉瑞和Novavax是本周必须持有的股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-11-29 10:38</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might significantly reduce the effectiveness of first-generation COVID-19 vaccines.</p><p><blockquote>上周五，新出现的奥密克戎冠状病毒变种震惊了美国股市。奥密克戎让世界感到紧张，因为其独特的突变组合可能会显着降低第一代COVID-19疫苗的有效性。</blockquote></p><p> While there simply isn't enough data to draw any firm conclusions about the seriousness of the omicron variant yet, politicians across the world were quick to react by imposing travel bans and restrictions on several African nations over the weekend. These rapid-fire travel restrictions make it abundantly clear that the global pandemic -- and its effects on the world economy -- are far from over.</p><p><blockquote>虽然还没有足够的数据对奥密克戎变种的严重性得出任何明确的结论，但世界各地的政界人士很快做出反应，周末对几个非洲国家实施了旅行禁令和限制。这些快速的旅行限制非常清楚地表明，全球疫情及其对世界经济的影响远未结束。</blockquote></p><p> How should investors protect their portfolios from this latest threat to global supply chains, international travel, and public health? The answer appears to be simple enough: vaccine stocks. On Black Friday, shares of the top COVID-19 vaccine developers <b>Moderna</b>(NASDAQ:MRNA),<b>Pfizer</b>(NYSE:PFE), and <b>Novavax</b>(NASDAQ:NVAX) all vaulted higher. Here's why these threebiopharmaceutical stocksought to continue to their march northward next week and beyond.</p><p><blockquote>投资者应该如何保护他们的投资组合免受全球供应链、国际旅行和公共卫生的最新威胁？答案似乎很简单：疫苗库存。黑色星期五，顶级COVID-19疫苗开发商的股票<b>现代</b>（纳斯达克：MRNA），<b>辉瑞</b>（纽约证券交易所代码：PFE），以及<b>Novavax</b>（纳斯达克：NVAX）全部走高。这就是为什么这三只生物制药股寻求在下周及以后继续北上。</blockquote></p><p> The pandemic's latest twist makes these three stocks screaming buys</p><p><blockquote>疫情的最新转折让这三只股票尖叫买入</blockquote></p><p> Moderna, Pfizer, and Novavax all enjoyed a sizable jump in their share prices during the holiday-shortened trading session on Friday thanks to their quick reaction to the omicron variant. Specifically, Moderna announced that it is working on an omicron-specific vaccine, as well a unique booster shot regimen, based on its currently authorized COVID-19 vaccine, that may provide a higher level of immune protection against this new variant.</p><p><blockquote>由于对奥密克戎变种的快速反应，Moderna、辉瑞和Novavax的股价在周五假期缩短的交易时段均大幅上涨。具体来说，Moderna宣布，它正在研究一种奥密克戎特异性疫苗，以及一种基于其目前授权的COVID-19疫苗的独特加强注射方案，这可能会针对这种新变种提供更高水平的免疫保护。</blockquote></p><p> Pfizer, for its part, said that its <b>BioNTech</b>-partnered COVID-19 vaccine can easily be tailored to the omicron variant and be ready for use within 100-days -- that is, if the original version of its vaccine fails to provide adequate protection. Novavax also provided an update on its omicron vaccine strategy last Friday, with the biotech saying that it plans on having an omicron-specific shot ready for testing and manufacturing within the next few weeks.</p><p><blockquote>辉瑞则表示，其<b>BioNTech</b>-合作的COVID-19疫苗可以很容易地适应奥密克戎变种，并在100天内准备好使用——也就是说，如果其疫苗的原始版本无法提供足够的保护。Novavax上周五还提供了其奥密克戎疫苗战略的最新情况，该生物技术公司表示，计划在未来几周内准备好一种针对奥密克戎的疫苗进行测试和生产。</blockquote></p><p> Why are these omicron-tailored vaccines a huge positive for their developers? The messenger RNA (mRNA) vaccines from Moderna and Pfizer/BioNTech both appeared to be on the back end of the commercial shelf lives prior to this news. As a result, Moderna's stock was in the midst of notable downward trend earlier this month. The sudden need for more potent booster shots and a potential variant-specific vaccine should keep Moderna's top line headed in the right direction in 2022, which ought to light a fire underneath the biotech's shares for the remainder of the year.</p><p><blockquote>为什么这些奥密克戎定制的疫苗对其开发者来说是一个巨大的积极因素？在这一消息发布之前，Moderna和辉瑞/BioNTech的信使RNA(mRNA)疫苗似乎都处于商业保质期的后端。因此，Moderna的股价本月早些时候出现了明显的下跌趋势。对更有效的加强注射和潜在的变异特异性疫苗的突然需求应该会使Moderna的营收在2022年朝着正确的方向发展，这应该会在今年剩余时间里点燃该生物技术公司的股价。</blockquote></p><p> While Pfizer's equity hasn't skipped a beat of late because of its oral coronavirus pill, the pharma giant now stands to possibly benefit from another year of exceptionally strong COVID-19 vaccine sales. Pfizer's stock, in turn, will probably continue to print ever-increasing record highs heading into 2022.</p><p><blockquote>虽然辉瑞的股价最近并没有因为其口服冠状病毒药物而下跌，但这家制药巨头现在可能会受益于又一年异常强劲的COVID-19疫苗销售。反过来，辉瑞的股价可能会在2022年继续创下历史新高。</blockquote></p><p> On the Novavax side of ledger, the biotech's shares are currently down by a whopping 31% from their 52-week highs. The vaccine specialist's shares have dipped in the back half of 2021 in response to manufacturing issues, regulatory delays, and a growing concern among investors that the company may have simply missed the boat.</p><p><blockquote>在ledger的Novavax方面，该生物技术公司的股价目前较52周高点下跌了31%。由于制造问题、监管延误以及投资者越来越担心该公司可能只是错过了机会，这家疫苗专家的股价在2021年下半年下跌。</blockquote></p><p> What's important to understand is that Novavax's COVID-19 vaccine is protein-based, which may appeal to a broad range of folks hesitant about cutting-edge mRNA vaccines. This new variant, therefore, ought to keep this latent demand for Novavax's alternative jab on the high side, as the company slowly completes the regulatory process in the all-important U.S. market.</p><p><blockquote>重要的是要了解Novavax的COVID-19疫苗是基于蛋白质的，这可能会吸引许多对尖端mRNA疫苗犹豫不决的人。因此，随着Novavax在非常重要的美国市场慢慢完成监管程序，这种新变种应该会保持对Novavax替代疫苗的潜在需求偏高。</blockquote></p><p> In short, Moderna, Pfizer, and Novavax are all poised to benefit in a big way from their unique vaccine development capabilities, making their stocks exceedingly strong buys this week.</p><p><blockquote>简而言之，Moderna、辉瑞和Novavax都有望从其独特的疫苗开发能力中受益匪浅，这使得它们的股票本周受到了极其强劲的买入。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/11/28/moderna-pfizer-and-novavax-are-must-own-stocks-thi/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/11/28/moderna-pfizer-and-novavax-are-must-own-stocks-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119853738","content_text":"The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might significantly reduce the effectiveness of first-generation COVID-19 vaccines.\nWhile there simply isn't enough data to draw any firm conclusions about the seriousness of the omicron variant yet, politicians across the world were quick to react by imposing travel bans and restrictions on several African nations over the weekend. These rapid-fire travel restrictions make it abundantly clear that the global pandemic -- and its effects on the world economy -- are far from over.\nHow should investors protect their portfolios from this latest threat to global supply chains, international travel, and public health? The answer appears to be simple enough: vaccine stocks. On Black Friday, shares of the top COVID-19 vaccine developers Moderna(NASDAQ:MRNA),Pfizer(NYSE:PFE), and Novavax(NASDAQ:NVAX) all vaulted higher. Here's why these threebiopharmaceutical stocksought to continue to their march northward next week and beyond.\nThe pandemic's latest twist makes these three stocks screaming buys\nModerna, Pfizer, and Novavax all enjoyed a sizable jump in their share prices during the holiday-shortened trading session on Friday thanks to their quick reaction to the omicron variant. Specifically, Moderna announced that it is working on an omicron-specific vaccine, as well a unique booster shot regimen, based on its currently authorized COVID-19 vaccine, that may provide a higher level of immune protection against this new variant.\nPfizer, for its part, said that its BioNTech-partnered COVID-19 vaccine can easily be tailored to the omicron variant and be ready for use within 100-days -- that is, if the original version of its vaccine fails to provide adequate protection. Novavax also provided an update on its omicron vaccine strategy last Friday, with the biotech saying that it plans on having an omicron-specific shot ready for testing and manufacturing within the next few weeks.\nWhy are these omicron-tailored vaccines a huge positive for their developers? The messenger RNA (mRNA) vaccines from Moderna and Pfizer/BioNTech both appeared to be on the back end of the commercial shelf lives prior to this news. As a result, Moderna's stock was in the midst of notable downward trend earlier this month. The sudden need for more potent booster shots and a potential variant-specific vaccine should keep Moderna's top line headed in the right direction in 2022, which ought to light a fire underneath the biotech's shares for the remainder of the year.\nWhile Pfizer's equity hasn't skipped a beat of late because of its oral coronavirus pill, the pharma giant now stands to possibly benefit from another year of exceptionally strong COVID-19 vaccine sales. Pfizer's stock, in turn, will probably continue to print ever-increasing record highs heading into 2022.\nOn the Novavax side of ledger, the biotech's shares are currently down by a whopping 31% from their 52-week highs. The vaccine specialist's shares have dipped in the back half of 2021 in response to manufacturing issues, regulatory delays, and a growing concern among investors that the company may have simply missed the boat.\nWhat's important to understand is that Novavax's COVID-19 vaccine is protein-based, which may appeal to a broad range of folks hesitant about cutting-edge mRNA vaccines. This new variant, therefore, ought to keep this latent demand for Novavax's alternative jab on the high side, as the company slowly completes the regulatory process in the all-important U.S. market.\nIn short, Moderna, Pfizer, and Novavax are all poised to benefit in a big way from their unique vaccine development capabilities, making their stocks exceedingly strong buys this week.","news_type":1,"symbols_score_info":{"PFE":0.9,"MRNA":0.9,"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2358,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600593147,"gmtCreate":1638167898293,"gmtModify":1638167898366,"author":{"id":"3583431682924843","authorId":"3583431682924843","name":"Tinktink","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583431682924843","authorIdStr":"3583431682924843"},"themes":[],"htmlText":"Thankd","listText":"Thankd","text":"Thankd","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/600593147","repostId":"1173149300","repostType":4,"isVote":1,"tweetType":1,"viewCount":2777,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872494256,"gmtCreate":1637556830656,"gmtModify":1637556830742,"author":{"id":"3583431682924843","authorId":"3583431682924843","name":"Tinktink","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583431682924843","authorIdStr":"3583431682924843"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872494256","repostId":"2185120826","repostType":4,"isVote":1,"tweetType":1,"viewCount":2122,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878762424,"gmtCreate":1637235057274,"gmtModify":1637235057390,"author":{"id":"3583431682924843","authorId":"3583431682924843","name":"Tinktink","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583431682924843","authorIdStr":"3583431682924843"},"themes":[],"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878762424","repostId":"1196614874","repostType":4,"repost":{"id":"1196614874","kind":"news","pubTimestamp":1637234017,"share":"https://www.laohu8.com/m/news/1196614874?lang=zh_CN&edition=full","pubTime":"2021-11-18 19:13","market":"us","language":"en","title":"Life sciences software startup Benchling files for U.S. listing -sources<blockquote>生命科学软件初创公司正在为美国上市做准备——消息人士</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1196614874","media":"Reuters","summary":"Benchling, which develops software tools for scientists and pharmaceutical research organizations, h","content":"<p>Benchling, which develops software tools for scientists and pharmaceutical research organizations, has confidentially submitted paperwork with regulators for a stock market listing in New York, according to people familiar with the matter.</p><p><blockquote>据知情人士透露，为科学家和制药研究机构开发软件工具的Benchling已秘密向监管机构提交了在纽约股市上市的文件。</blockquote></p><p> The San Francisco, California-based company, which was valued at $4 billion in a funding round earlier this year, is aiming to go public in early 2022 at a much higher valuation, the sources said.</p><p><blockquote>消息人士称，这家总部位于加利福尼亚州旧金山的公司在今年早些时候的一轮融资中估值为40亿美元，计划在2022年初以更高的估值上市。</blockquote></p><p> Benchling is considering going public through a direct listing, although the company has not ruled out a traditional IPO (initial public offering), sources said. One of its major investors on the board, Benchmark Capital, has been a vocal advocate of direct listings.</p><p><blockquote>消息人士称，Benchling正在考虑通过直接上市的方式上市，尽管该公司没有排除传统的IPO（首次公开募股）。其董事会的主要投资者之一Benchmark Capital一直是直接上市的直言不讳的倡导者。</blockquote></p><p> The start-up hired investment banks and other financial advisors earlier this year to advise on its listing plans, the sources said.</p><p><blockquote>消息人士称，这家初创公司今年早些时候聘请了投资银行和其他财务顾问为其上市计划提供建议。</blockquote></p><p> The sources, who requested anonymity as these discussions are confidential, cautioned that Benchling's go-public plans were subject to market conditions and could change. Benchling declined to comment.</p><p><blockquote>由于这些讨论是保密的，要求匿名的消息人士警告说，Benchling的上市计划取决于市场条件，可能会发生变化。Benchling拒绝置评。</blockquote></p><p> Founded in 2012 by Massachusetts Institute of Technology classmates Sajith Wickramasekara and Ashu Singhal, Benchling has emerged as a prominent player in a niche and growing market for digitizing the R&D process.</p><p><blockquote>Benchling由麻省理工学院的同学Sajith Wickramasekara和Ashu Singhal于2012年创立，现已成为R&D流程数字化利基和不断增长的市场中的重要参与者。</blockquote></p><p> Its valuation has soared since the beginning of 2020, when it was valued at less than $1 billion, as the company benefited from booming R&D investments in pharma and biotech companies. Benchling has so far raised roughly $350 million from venture capital investors including Sequoia Capital and Menlo Ventures.</p><p><blockquote>自2020年初以来，其估值飙升，当时的估值不到10亿美元，因为该公司受益于制药和生物技术公司蓬勃发展的研发投资。迄今为止，Benchling已从红杉资本和Menlo Ventures等风险资本投资者那里筹集了约3.5亿美元。</blockquote></p><p> Benchling offers customers a variety of software applications and technology platforms, including cloud-based tools and laboratory automation software. Its end-to-end workflow management system allows researchers to collaborate and track projects.</p><p><blockquote>Benchling为客户提供各种软件应用和技术平台，包括基于云的工具和实验室自动化软件。其端到端工作流管理系统允许研究人员协作和跟踪项目。</blockquote></p><p> According to its website, over 200,000 scientists currently use Benchling's technology tools. It counts numerous big names from the pharma, life sciences and biotech sectors, including Gilead Sciences , Sanofi, Regeneron, Gingko Bioworks, Zymergen, Lyell Immunopharma Inc and BP's Biosciences Center among its customers.</p><p><blockquote>根据其网站，目前有超过200,000名科学家使用Benchling的技术工具。其客户包括制药、生命科学和生物技术领域的众多知名企业，包括吉利德科学、赛诺菲、再生元、Gingko Bioworks、Zymergen、Lyell Immunopharma Inc和BP生物科学中心。</blockquote></p><p> Earlier this year, Benchling hired former LinkedIn executive Richard Wong as its chief financial officer as part of its plans to go public.</p><p><blockquote>今年早些时候，Benchling聘请LinkedIn前高管Richard Wong担任首席财务官，作为其上市计划的一部分。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Life sciences software startup Benchling files for U.S. listing -sources<blockquote>生命科学软件初创公司正在为美国上市做准备——消息人士</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLife sciences software startup Benchling files for U.S. listing -sources<blockquote>生命科学软件初创公司正在为美国上市做准备——消息人士</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-18 19:13</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Benchling, which develops software tools for scientists and pharmaceutical research organizations, has confidentially submitted paperwork with regulators for a stock market listing in New York, according to people familiar with the matter.</p><p><blockquote>据知情人士透露，为科学家和制药研究机构开发软件工具的Benchling已秘密向监管机构提交了在纽约股市上市的文件。</blockquote></p><p> The San Francisco, California-based company, which was valued at $4 billion in a funding round earlier this year, is aiming to go public in early 2022 at a much higher valuation, the sources said.</p><p><blockquote>消息人士称，这家总部位于加利福尼亚州旧金山的公司在今年早些时候的一轮融资中估值为40亿美元，计划在2022年初以更高的估值上市。</blockquote></p><p> Benchling is considering going public through a direct listing, although the company has not ruled out a traditional IPO (initial public offering), sources said. One of its major investors on the board, Benchmark Capital, has been a vocal advocate of direct listings.</p><p><blockquote>消息人士称，Benchling正在考虑通过直接上市的方式上市，尽管该公司没有排除传统的IPO（首次公开募股）。其董事会的主要投资者之一Benchmark Capital一直是直接上市的直言不讳的倡导者。</blockquote></p><p> The start-up hired investment banks and other financial advisors earlier this year to advise on its listing plans, the sources said.</p><p><blockquote>消息人士称，这家初创公司今年早些时候聘请了投资银行和其他财务顾问为其上市计划提供建议。</blockquote></p><p> The sources, who requested anonymity as these discussions are confidential, cautioned that Benchling's go-public plans were subject to market conditions and could change. Benchling declined to comment.</p><p><blockquote>由于这些讨论是保密的，要求匿名的消息人士警告说，Benchling的上市计划取决于市场条件，可能会发生变化。Benchling拒绝置评。</blockquote></p><p> Founded in 2012 by Massachusetts Institute of Technology classmates Sajith Wickramasekara and Ashu Singhal, Benchling has emerged as a prominent player in a niche and growing market for digitizing the R&D process.</p><p><blockquote>Benchling由麻省理工学院的同学Sajith Wickramasekara和Ashu Singhal于2012年创立，现已成为R&D流程数字化利基和不断增长的市场中的重要参与者。</blockquote></p><p> Its valuation has soared since the beginning of 2020, when it was valued at less than $1 billion, as the company benefited from booming R&D investments in pharma and biotech companies. Benchling has so far raised roughly $350 million from venture capital investors including Sequoia Capital and Menlo Ventures.</p><p><blockquote>自2020年初以来，其估值飙升，当时的估值不到10亿美元，因为该公司受益于制药和生物技术公司蓬勃发展的研发投资。迄今为止，Benchling已从红杉资本和Menlo Ventures等风险资本投资者那里筹集了约3.5亿美元。</blockquote></p><p> Benchling offers customers a variety of software applications and technology platforms, including cloud-based tools and laboratory automation software. Its end-to-end workflow management system allows researchers to collaborate and track projects.</p><p><blockquote>Benchling为客户提供各种软件应用和技术平台，包括基于云的工具和实验室自动化软件。其端到端工作流管理系统允许研究人员协作和跟踪项目。</blockquote></p><p> According to its website, over 200,000 scientists currently use Benchling's technology tools. It counts numerous big names from the pharma, life sciences and biotech sectors, including Gilead Sciences , Sanofi, Regeneron, Gingko Bioworks, Zymergen, Lyell Immunopharma Inc and BP's Biosciences Center among its customers.</p><p><blockquote>根据其网站，目前有超过200,000名科学家使用Benchling的技术工具。其客户包括制药、生命科学和生物技术领域的众多知名企业，包括吉利德科学、赛诺菲、再生元、Gingko Bioworks、Zymergen、Lyell Immunopharma Inc和BP生物科学中心。</blockquote></p><p> Earlier this year, Benchling hired former LinkedIn executive Richard Wong as its chief financial officer as part of its plans to go public.</p><p><blockquote>今年早些时候，Benchling聘请LinkedIn前高管Richard Wong担任首席财务官，作为其上市计划的一部分。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/life-sciences-software-startup-benchling-110000545.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/life-sciences-software-startup-benchling-110000545.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196614874","content_text":"Benchling, which develops software tools for scientists and pharmaceutical research organizations, has confidentially submitted paperwork with regulators for a stock market listing in New York, according to people familiar with the matter.\nThe San Francisco, California-based company, which was valued at $4 billion in a funding round earlier this year, is aiming to go public in early 2022 at a much higher valuation, the sources said.\nBenchling is considering going public through a direct listing, although the company has not ruled out a traditional IPO (initial public offering), sources said. One of its major investors on the board, Benchmark Capital, has been a vocal advocate of direct listings.\nThe start-up hired investment banks and other financial advisors earlier this year to advise on its listing plans, the sources said.\nThe sources, who requested anonymity as these discussions are confidential, cautioned that Benchling's go-public plans were subject to market conditions and could change. Benchling declined to comment.\nFounded in 2012 by Massachusetts Institute of Technology classmates Sajith Wickramasekara and Ashu Singhal, Benchling has emerged as a prominent player in a niche and growing market for digitizing the R&D process.\nIts valuation has soared since the beginning of 2020, when it was valued at less than $1 billion, as the company benefited from booming R&D investments in pharma and biotech companies. Benchling has so far raised roughly $350 million from venture capital investors including Sequoia Capital and Menlo Ventures.\nBenchling offers customers a variety of software applications and technology platforms, including cloud-based tools and laboratory automation software. Its end-to-end workflow management system allows researchers to collaborate and track projects.\nAccording to its website, over 200,000 scientists currently use Benchling's technology tools. It counts numerous big names from the pharma, life sciences and biotech sectors, including Gilead Sciences , Sanofi, Regeneron, Gingko Bioworks, Zymergen, Lyell Immunopharma Inc and BP's Biosciences Center among its customers.\nEarlier this year, Benchling hired former LinkedIn executive Richard Wong as its chief financial officer as part of its plans to go public.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":1876,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878831329,"gmtCreate":1637163890969,"gmtModify":1637163891041,"author":{"id":"3583431682924843","authorId":"3583431682924843","name":"Tinktink","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583431682924843","authorIdStr":"3583431682924843"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/878831329","repostId":"1198667964","repostType":4,"repost":{"id":"1198667964","kind":"news","pubTimestamp":1637135563,"share":"https://www.laohu8.com/m/news/1198667964?lang=zh_CN&edition=full","pubTime":"2021-11-17 15:52","market":"us","language":"en","title":"Apple Could Smash Its iPhone Holiday Sales Record. What That Means for the Stock.<blockquote>苹果可能会打破iPhone假日销售记录。这对股票意味着什么。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1198667964","media":"Barrons","summary":"Apple is on track to break its previous record for iPhone sales over the holiday period, according t","content":"<p>Apple is on track to break its previous record for iPhone sales over the holiday period, according to new analysis, which should pave the way for stock price gains.</p><p><blockquote>最新分析显示，苹果有望打破此前假期期间iPhone销量纪录，这将为股价上涨铺平道路。</blockquote></p><p> Heading into Black Friday next week, analysts at investment bank and broker Wedbush Securities said they see delivery times for the Apple iPhone 13 Pro lengthening. The team, led by Dan Ives, estimates that demand is outstripping supply by around 15% heading into the holiday season.</p><p><blockquote>进入下周的黑色星期五，投资银行和经纪商Wedbush Securities的分析师表示，他们认为苹果iPhone 13 Pro的交付时间将会延长。由丹·艾夫斯(Dan Ives)领导的团队估计，进入假期前，需求将超过供应约15%。</blockquote></p><p> Wait times have in the past been viewed as an indicator of demand for devices. But this year, in a world gripped by supply-chain issues, wait times for some models notching multiyear records might not be the clear green flag it would have been in the past.</p><p><blockquote>过去，等待时间被视为设备需求的指标。但今年，在一个受到供应链问题困扰的世界中，一些车型创下多年记录的等待时间可能不会像过去那样明显。</blockquote></p><p> Ives noted that Apple was dealing with the global shortage of semiconductors—a critical component in iPhones—and widespread supply-chain disruptions, but still he sees the tech giant smashing a key sales record.</p><p><blockquote>Ives指出，苹果正在应对全球半导体（iPhone的关键组件）短缺和广泛的供应链中断的问题，但他仍然认为这家科技巨头打破了关键的销售记录。</blockquote></p><p> “We estimate that Apple is on pace to sell ~40 million iPhones between Black Friday and Christmas, which would be record holiday pace for the company despite the lingering chip shortage limiting iPhone supply globally by roughly 10 million units based on our analysis,” Ives said.</p><p><blockquote>“我们估计，苹果将在黑色星期五和圣诞节之间销售约4000万部iPhone，这将是该公司创纪录的假期销售速度，尽管根据我们的分析，持续的芯片短缺使全球iPhone供应限制了约1000万部。”说。</blockquote></p><p> The team at Wedbush said that “tremendous demand trends” in the U.S. and China were a positive sign that Apple could sell more than 80 million iPhone units this quarter.</p><p><blockquote>Wedbush的团队表示，美国和中国的“巨大需求趋势”是一个积极的迹象，表明苹果本季度可能售出超过8000万部iPhone。</blockquote></p><p> That would be good for Apple investors, because, as <i>Barron’s</i> reporter Max A. Cherney wrote in September, “Apple stock practically lives and dies on the company’s iPhone sales every year.”</p><p><blockquote>这对苹果投资者来说是件好事，因为<i>巴伦周刊</i>记者Max A.Cherney在9月份写道，“苹果股票的生死几乎取决于该公司每年的iPhone销量。”</blockquote></p><p> Wedbush maintained its Outperform rating on Apple Tuesday and its $185 price target, which indicates around 24% upside.</p><p><blockquote>Wedbush周二维持苹果跑赢大盘的评级和185美元的目标价，这表明上涨空间约为24%。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Could Smash Its iPhone Holiday Sales Record. What That Means for the Stock.<blockquote>苹果可能会打破iPhone假日销售记录。这对股票意味着什么。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Could Smash Its iPhone Holiday Sales Record. What That Means for the Stock.<blockquote>苹果可能会打破iPhone假日销售记录。这对股票意味着什么。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-11-17 15:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Apple is on track to break its previous record for iPhone sales over the holiday period, according to new analysis, which should pave the way for stock price gains.</p><p><blockquote>最新分析显示，苹果有望打破此前假期期间iPhone销量纪录，这将为股价上涨铺平道路。</blockquote></p><p> Heading into Black Friday next week, analysts at investment bank and broker Wedbush Securities said they see delivery times for the Apple iPhone 13 Pro lengthening. The team, led by Dan Ives, estimates that demand is outstripping supply by around 15% heading into the holiday season.</p><p><blockquote>进入下周的黑色星期五，投资银行和经纪商Wedbush Securities的分析师表示，他们认为苹果iPhone 13 Pro的交付时间将会延长。由丹·艾夫斯(Dan Ives)领导的团队估计，进入假期前，需求将超过供应约15%。</blockquote></p><p> Wait times have in the past been viewed as an indicator of demand for devices. But this year, in a world gripped by supply-chain issues, wait times for some models notching multiyear records might not be the clear green flag it would have been in the past.</p><p><blockquote>过去，等待时间被视为设备需求的指标。但今年，在一个受到供应链问题困扰的世界中，一些车型创下多年记录的等待时间可能不会像过去那样明显。</blockquote></p><p> Ives noted that Apple was dealing with the global shortage of semiconductors—a critical component in iPhones—and widespread supply-chain disruptions, but still he sees the tech giant smashing a key sales record.</p><p><blockquote>Ives指出，苹果正在应对全球半导体（iPhone的关键组件）短缺和广泛的供应链中断的问题，但他仍然认为这家科技巨头打破了关键的销售记录。</blockquote></p><p> “We estimate that Apple is on pace to sell ~40 million iPhones between Black Friday and Christmas, which would be record holiday pace for the company despite the lingering chip shortage limiting iPhone supply globally by roughly 10 million units based on our analysis,” Ives said.</p><p><blockquote>“我们估计，苹果将在黑色星期五和圣诞节之间销售约4000万部iPhone，这将是该公司创纪录的假期销售速度，尽管根据我们的分析，持续的芯片短缺使全球iPhone供应限制了约1000万部。”说。</blockquote></p><p> The team at Wedbush said that “tremendous demand trends” in the U.S. and China were a positive sign that Apple could sell more than 80 million iPhone units this quarter.</p><p><blockquote>Wedbush的团队表示，美国和中国的“巨大需求趋势”是一个积极的迹象，表明苹果本季度可能售出超过8000万部iPhone。</blockquote></p><p> That would be good for Apple investors, because, as <i>Barron’s</i> reporter Max A. Cherney wrote in September, “Apple stock practically lives and dies on the company’s iPhone sales every year.”</p><p><blockquote>这对苹果投资者来说是件好事，因为<i>巴伦周刊</i>记者Max A.Cherney在9月份写道，“苹果股票的生死几乎取决于该公司每年的iPhone销量。”</blockquote></p><p> Wedbush maintained its Outperform rating on Apple Tuesday and its $185 price target, which indicates around 24% upside.</p><p><blockquote>Wedbush周二维持苹果跑赢大盘的评级和185美元的目标价，这表明上涨空间约为24%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/apple-iphone-holiday-sales-record-51637078986?mod=hp_DAY_3\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.barrons.com/articles/apple-iphone-holiday-sales-record-51637078986?mod=hp_DAY_3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198667964","content_text":"Apple is on track to break its previous record for iPhone sales over the holiday period, according to new analysis, which should pave the way for stock price gains.\nHeading into Black Friday next week, analysts at investment bank and broker Wedbush Securities said they see delivery times for the Apple iPhone 13 Pro lengthening. The team, led by Dan Ives, estimates that demand is outstripping supply by around 15% heading into the holiday season.\nWait times have in the past been viewed as an indicator of demand for devices. But this year, in a world gripped by supply-chain issues, wait times for some models notching multiyear records might not be the clear green flag it would have been in the past.\nIves noted that Apple was dealing with the global shortage of semiconductors—a critical component in iPhones—and widespread supply-chain disruptions, but still he sees the tech giant smashing a key sales record.\n“We estimate that Apple is on pace to sell ~40 million iPhones between Black Friday and Christmas, which would be record holiday pace for the company despite the lingering chip shortage limiting iPhone supply globally by roughly 10 million units based on our analysis,” Ives said.\nThe team at Wedbush said that “tremendous demand trends” in the U.S. and China were a positive sign that Apple could sell more than 80 million iPhone units this quarter.\nThat would be good for Apple investors, because, as Barron’s reporter Max A. Cherney wrote in September, “Apple stock practically lives and dies on the company’s iPhone sales every year.”\nWedbush maintained its Outperform rating on Apple Tuesday and its $185 price target, which indicates around 24% upside.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":2570,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873859655,"gmtCreate":1636931802826,"gmtModify":1636931802891,"author":{"id":"3583431682924843","authorId":"3583431682924843","name":"Tinktink","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583431682924843","authorIdStr":"3583431682924843"},"themes":[],"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873859655","repostId":"1130613433","repostType":4,"repost":{"id":"1130613433","kind":"news","pubTimestamp":1636854571,"share":"https://www.laohu8.com/m/news/1130613433?lang=zh_CN&edition=full","pubTime":"2021-11-14 09:49","market":"us","language":"en","title":"7 Earnings Reports to Watch Next Week<blockquote>下周值得关注的7份财报</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1130613433","media":"InvestorPlace","summary":"A parade of retailers report earnings as their share prices remain buoyant\nSource: Shutterstock\nReta","content":"<p><div> A parade of retailers report earnings as their share prices remain buoyant Source: Shutterstock Retailers and big box chains take center stage next week as the earnings train rolls on. And these ...</p><p><blockquote><div>随着股价保持强劲，众多零售商公布了财报资料来源：Shutterstock随着财报列车的继续，零售商和大型连锁店将成为下周的中心舞台。还有这些...</div></blockquote></p><p> <a href=\"https://investorplace.com/earnings-reports-to-watch-next-week/\">网页链接</a> </div> </p><p><blockquote><a href=\"https://investorplace.com/earnings-reports-to-watch-next-week/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Earnings Reports to Watch Next Week<blockquote>下周值得关注的7份财报</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Earnings Reports to Watch Next Week<blockquote>下周值得关注的7份财报</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-11-14 09:49</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> A parade of retailers report earnings as their share prices remain buoyant Source: Shutterstock Retailers and big box chains take center stage next week as the earnings train rolls on. And these ...</p><p><blockquote><div>随着股价保持强劲，众多零售商公布了财报资料来源：Shutterstock随着财报列车的继续，零售商和大型连锁店将成为下周的中心舞台。还有这些...</div></blockquote></p><p> <a href=\"https://investorplace.com/earnings-reports-to-watch-next-week/\">网页链接</a> </div> </p><p><blockquote><a href=\"https://investorplace.com/earnings-reports-to-watch-next-week/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/earnings-reports-to-watch-next-week/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LZB":"La-Z-Boy家具","LOW":"劳氏","M":"梅西百货","WMT":"沃尔玛","TGT":"塔吉特","HD":"家得宝"},"source_url":"https://investorplace.com/earnings-reports-to-watch-next-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130613433","content_text":"A parade of retailers report earnings as their share prices remain buoyant\nSource: Shutterstock\nRetailers and big box chains take center stage next week as the earnings train rolls on. And these earnings come as we enter the pivotal holiday sales season, which can make or break retailers large and small.\nAnalysts on Wall Street will be carefully parsing next week’s results to gain insights into how the economic reopening is holding up, and, in particular, how consumer spending performed heading into the fourth and final quarter of the year.\nIt has been a good run for stocks of retailers in recent weeks, with the SPDR S&P Retail ETF(NYSEARCA:XRT) up 15% over the past month. Sentiment regarding retailers has turned bullish as we approach the lucrative holiday sales period and the twin events of Black Friday and Cyber Monday.\nStrong earnings reports from key retail companies are likely to keep stocks across the sector buoyant as we near year-end.Here are seven retail stocks reporting earnings the week of Nov. 15.\n\nWalmart(NYSE:WMT)\nHome Depot(NYSE:HD)\nLa-Z-Boy(NYSE:LZB)\nLowe’s(NYSE:LOW)\nTarget(NYSE:TGT)\nMacy’s(NYSE:M)\nFoot Locker(NYSE:FL)\n\nWalmart (WMT)\nFirst out of the gate next week is Walmart, the world’s biggest retailer with more than 10,000 stores, 2.3 million employees and annual revenues of nearly $550 billion.\nThe retail colossus survived the pandemic largely by ramping up its online sales strategy, and its brick-and-mortar stores have been recovering this year as the economy reopens.\nHowever, despite its efforts and success, Walmart’s stock has underperformed, rising only 1% year-to-date at $148.50 a share. In the past 52 weeks, WMT stock has gained a slight 0.35%. The tepid growth has frustrated Walmart shareholders who have had to watch while rival retail stocks have risen more than 50% this year.\nA strong third-quarter report from Walmart could give the share price a much needed boost.Wall Street is looking for the company to report earnings per share (EPS) of $1.40 on revenues of $135.52 billion. Any beat to the upside will be well-received and could be the catalyst needed to finally move the needle on WMT stock.\nThe company has received several bullish analyst ratings recently, with Goldman Sachs(NYSE:GS) adding the stockto its “conviction buy” list in October. The median price target on the stock, among 19 analysts who cover Walmart, is $170, which is 15% higher than its current level.\nHome Depot (HD)\nAlso reporting Q3 results next week is home improvement retailer Home Depot. The Atlanta-headquartered company has seemingly had it both ways during the pandemic. The company performed well during Covid-19 lockdowns as people focused on fixing up their homes, and has continued to perform well this year as the economic recovery accelerated.\nYear-to-date, HD stock is up nearly 40% at $367.55 per share. And despite the bull run, Home Depot’s share price has continued to trend upward, rising nearly 10% since the start of October. The company is no doubt looking to finish the year strong and keep the momentum in its stock going with its third-quarter results.\nAnalysts are forecasting that Home Depot will report EPS of $3.36 on revenues of $34.69 billion for Q3. This would be after the company reported that its sales in this year’s second quarter increased 8.1% from a year ago to $41 billion, the first time in the company’s history that its quarterly sales surpassed $40 billion.\nWith home prices continuing to rise in the U.S.,up 20% in August this year from the same month of 2020 according to the Federal Reserve Bank of St. Louis, homeowners seem content to continue taking equity out of their domicile and spending it to improve its value, which benefits Home Depot.\nLa-Z-Boy (LZB)\nFurniture manufacturer La-Z-Boy, which is known for its signature brand of upholstered recliners, reports earnings next week as it shares finally breakout after being down for most of this year.\nOver the last month, LZB stock has gained 12% and now trades at $11.43 a share. However, even with that strong performance, the stock remains down 7% on the year. Strong third-quarter results heading into the holidays could accelerate the growth of La-Z-Boy’s stock.\nAnalysts expect the company to announce Q3 EPS of 73 cents on revenues of $540 million. La-Z-Boy has outperformed Wall Street’s earnings expectations in the four previous quarters. Overall, La-Z-Boy has grown its revenues by 9.5% and grown its net income by 32.3% since 2018. The furniture retailer is also praised for having a clean balance sheet with $391.21 million in cash on hand and $362.64 million in total debt.\nAnalysts will be watching La-Z-Boy to see if global supply constraints have materially impacted its business or will do so going forward.\nLowe’s (LOW)\nLowe’s, the home improvement retailer and main rival of Home Depot, also reports next week. And, as with Home Depot, Lowe’s stock has been a strong outperformer this year, up a total of 45% to $232.76 a share.\nThe rally in LOW stock has gathered steam in recent weeks, with the share price climbing 11% over the last month. The stellar stock performance has been propelled by exceptional sales that reached a record $27.6 billion in Lowe’s previous quarterly report.\nEqually impressive is the fact that Lowe’s says it now generates 25% of its revenues from professionals such as contractors, electricians and plumbers. It is those professionals that are highly coveted by both Lowe’s and Home Depot as consistent repeat customers.\nIn an effort to attract even more professional customers and keep its sales in record territory, Lowe’s has beendesigning more intuitive store layouts based on helping contractors and other trades find everything they need for a specific job without having to search the entire store.\nAdditionally, the company has moved its website “Lowe’s for Pros” to the cloud, which enabled the company to add enhanced features, faster updates, and provide more personalized offers to those highly sought after professionals.Analysts have forecast that Lowe’s will announce EPS of $2.31 on revenues of $21.77 billion for its most recent quarter.\nTarget (TGT)\nTarget has been yet another top performer among retail stocks, up 44% so far in 2021 and up 60% in the last 52-weeks. At $256.26. TGT stock has run uninterrupted all year.\nHowever, some analysts are raising concerns that the rally could be running out of steam. When Goldman Sachs added Walmart to its conviction list in October, the investment bank removed Target, stating that is expects slower growth from the Minneapolis-based company next year that is more inline with its historic performance. Target will be looking to prove the naysayers wrong when it announces its Q3 results.\nMuch of Target’s turnaround over the past few years is attributed to CEOBrian Cornell, who took over in 2014 as the company was dealing with a data breach that exposed the debit and credit card information of 40 million customers and its expansion into Canada was failing and dragging on the bottom line.\nCornell made the decision to exit Canada and has since invested heavily in e-commerce and brand name apparel. The moves proved to be the right ones judging by TGT stock, which is up 236% over the past five years. For next week’s earnings,Wall Street is anticipating EPS of $2.81 on revenues of $24.59 billion.\nMacy’s (M)\nMacy’s has not only been a top-performing retail stock, it has been one of the best performing of all stocks this year. Since January, Macy’s share price has increased 175% to its current level of $30.89. In the last month alone, M stock has gained 36%. The company has left its competitors in the dust as its shares continue rising higher and higher.\nMacy’s now has a market capitalization approaching $10 billion. The incredible growth is due to a strong e-commerce strategy that has propelled shares higher. Although some analysts have claimed that Macy’s share price appreciation is due to it being treated as a meme stock by retail investors.\nFounded in 1858, Macy’s today operates more than nearly 800 stores under the Macy’s, Bloomingdale’s and Bluemercury brands. The company has recently been targeted by activist group Jana Partners, which is trying to force Macy’s to spin-off its successful and lucrative e-commerce business, which Jana Partners has estimated could be worth $15 billion.\nThe reaction to Jana Partners efforts has been largely negative and it looks as though Macy’s will control its own destiny when it comes to its e-commerce platform. For its latest earnings, analysts forecast Macy’s will report EPS of $0.29 on revenues of $5.18 billion.\nFoot Locker (FL)\nNew York-based footwear and apparel retailer Foot Locker’s latest earnings report comes as its stock has risen 15% in the last month, bringing year-to-date gains to 37%. At $53.86 a share, FL stock is now up nearly 50% in the past 52-weeks.\nThe company just announced that it is launching a brand new apparel line called “LCKR” that is focused on casual wear such as pullover hoodies and sweatpants. Foot Locker enlisted popular rapper Gunna to be the face of its newest brand, which officially launched Oct. 20 and should help boost sales heading into the New Year.\nThe company also recently completed a $360 million acquisition of Japanese retailer Atmos, which sells premium sneakers and apparel at 49 stores around the world, including 39 in Japan. The deal helps to expand Foot Locker globally as the company seeks growth opportunities outside its American home market.\nAnalysts have praised Foot Locker for its recent moves aimed at expanding its brand and operations. When it announces earnings next week,Wall Street is looking for the company to report EPS of $1.35 and revenues of $2.12 billion.","news_type":1,"symbols_score_info":{"M":0.9,"LZB":0.9,"LOW":0.9,"FL":0.9,"TGT":0.9,"WMT":0.9,"HD":0.9}},"isVote":1,"tweetType":1,"viewCount":2166,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847517164,"gmtCreate":1636535159205,"gmtModify":1636535159398,"author":{"id":"3583431682924843","authorId":"3583431682924843","name":"Tinktink","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583431682924843","authorIdStr":"3583431682924843"},"themes":[],"htmlText":"Thanks ","listText":"Thanks ","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847517164","repostId":"1186621175","repostType":4,"isVote":1,"tweetType":1,"viewCount":2249,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":840941396,"gmtCreate":1635579916711,"gmtModify":1635579935542,"author":{"id":"3583431682924843","authorId":"3583431682924843","name":"Tinktink","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583431682924843","authorIdStr":"3583431682924843"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/840941396","repostId":"1164427432","repostType":4,"repost":{"id":"1164427432","kind":"news","pubTimestamp":1635575541,"share":"https://www.laohu8.com/m/news/1164427432?lang=zh_CN&edition=full","pubTime":"2021-10-30 14:32","market":"hk","language":"en","title":"Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought<blockquote>凯西·伍德(Cathie Wood)逢低买入：她刚刚买入的3只股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164427432","media":"Motley Fool","summary":"Key Points\n\nARK Invest added to its Twilio, Teladoc Health, and Robinhood positions on Thursday.\nTwi","content":"<p>Key Points</p><p><blockquote>要点</blockquote></p><p> <ul> <li>ARK Invest added to its Twilio, Teladoc Health, and Robinhood positions on Thursday.</li> <li>Twilio and Robinhood have been falling since reporting financial results earlier this week.</li> <li>Teladoc bounced after its quarterly report but is still a market laggard this year.</li> </ul> <b>Motley Fool Issues Rare “All In” Buy Alert</b></p><p><blockquote><ul><li>ARK Invest周四增持了Twilio、Teladoc Health和Robinhood的头寸。</li><li>自本周早些时候公布财务业绩以来，Twilio和Robinhood一直在下跌。</li><li>Teladoc在发布季度报告后反弹，但今年仍落后于市场。</li></ul><b>Motley Fool发布罕见的“全押”买入警报</b></blockquote></p><p> Cathie Wood has become the best-known fund manager for risk-tolerant growth investors. Her penchant for unearthing disruptive stocks has made Wood -- as ARK Invest's CEO, chief investment officer, and founder -- a name for investors to watch. Herexchange-traded fundswere among last year's biggest gainers, and after a rough start in 2021, ARK Invest is starting to find its groove.</p><p><blockquote>凯西·伍德(Cathie Wood)已成为风险承受型成长型投资者最知名的基金经理。作为ARK Invest的首席执行官、首席投资官和创始人，伍德对挖掘颠覆性股票的爱好使她成为投资者关注的名字。她的交易所交易基金是去年涨幅最大的基金之一，在经历了2021年的艰难开局之后，ARK Invest开始找到自己的最佳状态。</blockquote></p><p> Every pick isn't a winner for Wood, but ARK Invest isn't afraid to buy stocks that Wood believes in when they take a hit. On Thursday, she added to her stakes in<b>Twilio</b> (NYSE:TWLO),<b>Teladoc Health</b>(NYSE:TDOC), and<b>Robinhood Markets</b>(NASDAQ:HOOD). Twilio and Robinhood were hit hard after reported quarterly results this week. Teladoc moved higher after reporting but is trading well below its all-time high. Let's take a closer look.</p><p><blockquote>对于伍德来说，并非每一个选择都是赢家，但ARK Invest并不害怕购买伍德在遭受打击时相信的股票。周四，她增持了<b>Twilio</b>（纽约证券交易所代码：TWLO），<b>Teladoc健康</b>（纽约证券交易所代码：TDOC），以及<b>罗宾汉市场</b>（纳斯达克：胡德）。Twilio和Robinhood在本周公布季度业绩后遭受重创。Teladoc在报告发布后走高，但交易价格远低于历史高点。让我们仔细看看。</blockquote></p><p> IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p> Shares of Twilio plummeted 18% on Thursday after the company reporteddisappointing financial results, and Wood was buying during the intraday weakness. The provider of in-app communication solutions beat expectations for the third quarter, posting stronger-than-expected revenue growth of 65% and a smaller-than-projected loss.</p><p><blockquote>周四，Twilio公布令人失望的财务业绩后，该公司股价暴跌18%，伍德在盘中疲软期间买入。这家应用内通信解决方案提供商第三季度的业绩超出预期，收入增长65%强于预期，亏损小于预期。</blockquote></p><p> Unfortunately there were some pressure points, and at least five analysts would go on to slash their price targets on the stock following the report. Twilio's guidance calls for a much larger loss than analysts were modeling, and some Wall Street pros are voicing concerns about the state of gross margins at the company.</p><p><blockquote>不幸的是，存在一些压力点，在报告发布后，至少有五位分析师将继续大幅削减该股的目标价。Twilio的指导评级的亏损比分析师预测的要大得多，一些华尔街专业人士对该公司的毛利率状况表示担忧。</blockquote></p><p> There's also the matter of the quality of its revenue. Twilio's been a growth star since hitting the market at $15 five years ago. It has clocked in with year-over-year revenue growth of at least 40%, and that pace was accelerating. Twilio's top line rose 55% last year, 64% through the first half of this year, and now 65% in its latest report.</p><p><blockquote>还有收入质量的问题。自五年前以15美元的价格上市以来，Twilio一直是增长之星。该公司的收入同比增长至少40%，而且这一速度还在加速。Twilio的营收去年增长了55%，今年上半年增长了64%，在最新报告中增长了65%。</blockquote></p><p> However, a good chunk of its recent growth has come from acquisitions, and the 38% in organic revenue growth it just served up for the third quarter could be problematic. The silver lining here is that the stock has fallen so hard since its peak that even the sharply reduced price targets are higher than where Twilio is trading now.</p><p><blockquote>然而，其最近的增长很大一部分来自收购，第三季度38%的有机收入增长可能会出现问题。这里的一线希望是，该股自峰值以来跌幅如此之大，即使大幅下调的目标价也高于Twilio目前的交易价格。</blockquote></p><p> Telehealth was all the rage during the pandemic. When we couldn't go visit a doctor, therapist, dietician, or other medical specialist, Teladoc was there with its easily accessible and affordable videoconferencing platform.</p><p><blockquote>远程医疗在疫情期间风靡一时。当我们无法去看医生、治疗师、营养师或其他医学专家时，Teladoc提供了易于访问且价格合理的视频会议平台。</blockquote></p><p> Teladoc'sfinancial updateon Wednesday afternoon was a mixed bag. It beat expectations on both ends of the income statement, but like Twilio, its guidance also calls for more red ink than analysts were forecasting. At least 10 analysts would go on to lower their price targets on the stock, but the shares still moved higher on Thursday.</p><p><blockquote>Teladoc周三下午的财务更新好坏参半。它的损益表两端都超出了预期，但与Twilio一样，其指引也评级了超出分析师预测的亏损。至少有10名分析师将继续下调该股的目标价，但该股周四仍走高。</blockquote></p><p> Business is still growing at Teladoc, and the company expects to facilitate more than 14.5 million visits this year. It's standing out despite the growingly competitive marketplace for telehealth.</p><p><blockquote>Teladoc的业务仍在增长，该公司预计今年的访问量将超过1450万次。尽管远程医疗市场竞争日益激烈，但它仍然脱颖而出。</blockquote></p><p> The quarterly report wasn't great, but since the stock has already shed more than half of its value since hitting all-time highs in February, the news came as a relief. Teladoc continues to be ARK Invest's second-largest holding across all of its ETFs, and on Thursday, Wood purchased more shares in four of the funds.</p><p><blockquote>季度报告并不出色，但由于该股自2月份触及历史高点以来已下跌一半以上，因此这一消息令人松了一口气。Teladoc仍然是ARK Invest所有ETF中的第二大持股，周四，Wood购买了其中四只基金的更多股票。</blockquote></p><p> Robinhood Markets is now a broken IPO, buckling below its $38 debutante price tag after a brutal quarterly report. You can take your pick at which of the numbers tripped up the online-trading platform.</p><p><blockquote>Robinhood Markets现在是一次失败的IPO，在发布了一份残酷的季度报告后，其首次公开募股价格跌破了38美元。你可以选择哪些数字让在线交易平台出错。</blockquote></p><p> We can start with the 35% growth in revenue that was well shy of the 60% growth that Wall Street was expecting. Guidance was also problematic. There was also a sequential dip in monthly active users.</p><p><blockquote>我们可以从35%的收入增长开始，这远低于华尔街预期的60%的增长。指导也有问题。月活跃用户也连续下降。</blockquote></p><p> The trends aren't kind here. Losses are only getting larger, and average revenue per user is sliding.</p><p><blockquote>这里的趋势并不好。损失只会越来越大，每个用户的平均收入也在下滑。</blockquote></p><p> Robinhood Markets traded as high as $85 on its fifth day of trading this summer, and now it's a broken IPO. Wood is buying the dip, but Robinhood Markets is going to have to introduce new features to stand out in an environment where traders are heading elsewhere.</p><p><blockquote>Robinhood Markets在今年夏天的第五个交易日的交易价格高达85美元，现在它是一个破发的IPO。伍德正在逢低买入，但Robinhood Markets将不得不引入新功能，才能在交易者转向其他地方的环境中脱颖而出。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought<blockquote>凯西·伍德(Cathie Wood)逢低买入：她刚刚买入的3只股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought<blockquote>凯西·伍德(Cathie Wood)逢低买入：她刚刚买入的3只股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-10-30 14:32</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Key Points</p><p><blockquote>要点</blockquote></p><p> <ul> <li>ARK Invest added to its Twilio, Teladoc Health, and Robinhood positions on Thursday.</li> <li>Twilio and Robinhood have been falling since reporting financial results earlier this week.</li> <li>Teladoc bounced after its quarterly report but is still a market laggard this year.</li> </ul> <b>Motley Fool Issues Rare “All In” Buy Alert</b></p><p><blockquote><ul><li>ARK Invest周四增持了Twilio、Teladoc Health和Robinhood的头寸。</li><li>自本周早些时候公布财务业绩以来，Twilio和Robinhood一直在下跌。</li><li>Teladoc在发布季度报告后反弹，但今年仍落后于市场。</li></ul><b>Motley Fool发布罕见的“全押”买入警报</b></blockquote></p><p> Cathie Wood has become the best-known fund manager for risk-tolerant growth investors. Her penchant for unearthing disruptive stocks has made Wood -- as ARK Invest's CEO, chief investment officer, and founder -- a name for investors to watch. Herexchange-traded fundswere among last year's biggest gainers, and after a rough start in 2021, ARK Invest is starting to find its groove.</p><p><blockquote>凯西·伍德(Cathie Wood)已成为风险承受型成长型投资者最知名的基金经理。作为ARK Invest的首席执行官、首席投资官和创始人，伍德对挖掘颠覆性股票的爱好使她成为投资者关注的名字。她的交易所交易基金是去年涨幅最大的基金之一，在经历了2021年的艰难开局之后，ARK Invest开始找到自己的最佳状态。</blockquote></p><p> Every pick isn't a winner for Wood, but ARK Invest isn't afraid to buy stocks that Wood believes in when they take a hit. On Thursday, she added to her stakes in<b>Twilio</b> (NYSE:TWLO),<b>Teladoc Health</b>(NYSE:TDOC), and<b>Robinhood Markets</b>(NASDAQ:HOOD). Twilio and Robinhood were hit hard after reported quarterly results this week. Teladoc moved higher after reporting but is trading well below its all-time high. Let's take a closer look.</p><p><blockquote>对于伍德来说，并非每一个选择都是赢家，但ARK Invest并不害怕购买伍德在遭受打击时相信的股票。周四，她增持了<b>Twilio</b>（纽约证券交易所代码：TWLO），<b>Teladoc健康</b>（纽约证券交易所代码：TDOC），以及<b>罗宾汉市场</b>（纳斯达克：胡德）。Twilio和Robinhood在本周公布季度业绩后遭受重创。Teladoc在报告发布后走高，但交易价格远低于历史高点。让我们仔细看看。</blockquote></p><p> IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p> Shares of Twilio plummeted 18% on Thursday after the company reporteddisappointing financial results, and Wood was buying during the intraday weakness. The provider of in-app communication solutions beat expectations for the third quarter, posting stronger-than-expected revenue growth of 65% and a smaller-than-projected loss.</p><p><blockquote>周四，Twilio公布令人失望的财务业绩后，该公司股价暴跌18%，伍德在盘中疲软期间买入。这家应用内通信解决方案提供商第三季度的业绩超出预期，收入增长65%强于预期，亏损小于预期。</blockquote></p><p> Unfortunately there were some pressure points, and at least five analysts would go on to slash their price targets on the stock following the report. Twilio's guidance calls for a much larger loss than analysts were modeling, and some Wall Street pros are voicing concerns about the state of gross margins at the company.</p><p><blockquote>不幸的是，存在一些压力点，在报告发布后，至少有五位分析师将继续大幅削减该股的目标价。Twilio的指导评级的亏损比分析师预测的要大得多，一些华尔街专业人士对该公司的毛利率状况表示担忧。</blockquote></p><p> There's also the matter of the quality of its revenue. Twilio's been a growth star since hitting the market at $15 five years ago. It has clocked in with year-over-year revenue growth of at least 40%, and that pace was accelerating. Twilio's top line rose 55% last year, 64% through the first half of this year, and now 65% in its latest report.</p><p><blockquote>还有收入质量的问题。自五年前以15美元的价格上市以来，Twilio一直是增长之星。该公司的收入同比增长至少40%，而且这一速度还在加速。Twilio的营收去年增长了55%，今年上半年增长了64%，在最新报告中增长了65%。</blockquote></p><p> However, a good chunk of its recent growth has come from acquisitions, and the 38% in organic revenue growth it just served up for the third quarter could be problematic. The silver lining here is that the stock has fallen so hard since its peak that even the sharply reduced price targets are higher than where Twilio is trading now.</p><p><blockquote>然而，其最近的增长很大一部分来自收购，第三季度38%的有机收入增长可能会出现问题。这里的一线希望是，该股自峰值以来跌幅如此之大，即使大幅下调的目标价也高于Twilio目前的交易价格。</blockquote></p><p> Telehealth was all the rage during the pandemic. When we couldn't go visit a doctor, therapist, dietician, or other medical specialist, Teladoc was there with its easily accessible and affordable videoconferencing platform.</p><p><blockquote>远程医疗在疫情期间风靡一时。当我们无法去看医生、治疗师、营养师或其他医学专家时，Teladoc提供了易于访问且价格合理的视频会议平台。</blockquote></p><p> Teladoc'sfinancial updateon Wednesday afternoon was a mixed bag. It beat expectations on both ends of the income statement, but like Twilio, its guidance also calls for more red ink than analysts were forecasting. At least 10 analysts would go on to lower their price targets on the stock, but the shares still moved higher on Thursday.</p><p><blockquote>Teladoc周三下午的财务更新好坏参半。它的损益表两端都超出了预期，但与Twilio一样，其指引也评级了超出分析师预测的亏损。至少有10名分析师将继续下调该股的目标价，但该股周四仍走高。</blockquote></p><p> Business is still growing at Teladoc, and the company expects to facilitate more than 14.5 million visits this year. It's standing out despite the growingly competitive marketplace for telehealth.</p><p><blockquote>Teladoc的业务仍在增长，该公司预计今年的访问量将超过1450万次。尽管远程医疗市场竞争日益激烈，但它仍然脱颖而出。</blockquote></p><p> The quarterly report wasn't great, but since the stock has already shed more than half of its value since hitting all-time highs in February, the news came as a relief. Teladoc continues to be ARK Invest's second-largest holding across all of its ETFs, and on Thursday, Wood purchased more shares in four of the funds.</p><p><blockquote>季度报告并不出色，但由于该股自2月份触及历史高点以来已下跌一半以上，因此这一消息令人松了一口气。Teladoc仍然是ARK Invest所有ETF中的第二大持股，周四，Wood购买了其中四只基金的更多股票。</blockquote></p><p> Robinhood Markets is now a broken IPO, buckling below its $38 debutante price tag after a brutal quarterly report. You can take your pick at which of the numbers tripped up the online-trading platform.</p><p><blockquote>Robinhood Markets现在是一次失败的IPO，在发布了一份残酷的季度报告后，其首次公开募股价格跌破了38美元。你可以选择哪些数字让在线交易平台出错。</blockquote></p><p> We can start with the 35% growth in revenue that was well shy of the 60% growth that Wall Street was expecting. Guidance was also problematic. There was also a sequential dip in monthly active users.</p><p><blockquote>我们可以从35%的收入增长开始，这远低于华尔街预期的60%的增长。指导也有问题。月活跃用户也连续下降。</blockquote></p><p> The trends aren't kind here. Losses are only getting larger, and average revenue per user is sliding.</p><p><blockquote>这里的趋势并不好。损失只会越来越大，每个用户的平均收入也在下滑。</blockquote></p><p> Robinhood Markets traded as high as $85 on its fifth day of trading this summer, and now it's a broken IPO. Wood is buying the dip, but Robinhood Markets is going to have to introduce new features to stand out in an environment where traders are heading elsewhere.</p><p><blockquote>Robinhood Markets在今年夏天的第五个交易日的交易价格高达85美元，现在它是一个破发的IPO。伍德正在逢低买入，但Robinhood Markets将不得不引入新功能，才能在交易者转向其他地方的环境中脱颖而出。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/10/29/cathie-wood-goes-bargain-hunting-3-stocks-she-just/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/5caed408891c5ae9176e1a31289a0785","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/10/29/cathie-wood-goes-bargain-hunting-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164427432","content_text":"Key Points\n\nARK Invest added to its Twilio, Teladoc Health, and Robinhood positions on Thursday.\nTwilio and Robinhood have been falling since reporting financial results earlier this week.\nTeladoc bounced after its quarterly report but is still a market laggard this year.\n\nMotley Fool Issues Rare “All In” Buy Alert\nCathie Wood has become the best-known fund manager for risk-tolerant growth investors. Her penchant for unearthing disruptive stocks has made Wood -- as ARK Invest's CEO, chief investment officer, and founder -- a name for investors to watch. Herexchange-traded fundswere among last year's biggest gainers, and after a rough start in 2021, ARK Invest is starting to find its groove.\nEvery pick isn't a winner for Wood, but ARK Invest isn't afraid to buy stocks that Wood believes in when they take a hit. On Thursday, she added to her stakes inTwilio (NYSE:TWLO),Teladoc Health(NYSE:TDOC), andRobinhood Markets(NASDAQ:HOOD). Twilio and Robinhood were hit hard after reported quarterly results this week. Teladoc moved higher after reporting but is trading well below its all-time high. Let's take a closer look.\nIMAGE SOURCE: GETTY IMAGES.\nShares of Twilio plummeted 18% on Thursday after the company reporteddisappointing financial results, and Wood was buying during the intraday weakness. The provider of in-app communication solutions beat expectations for the third quarter, posting stronger-than-expected revenue growth of 65% and a smaller-than-projected loss.\nUnfortunately there were some pressure points, and at least five analysts would go on to slash their price targets on the stock following the report. Twilio's guidance calls for a much larger loss than analysts were modeling, and some Wall Street pros are voicing concerns about the state of gross margins at the company.\nThere's also the matter of the quality of its revenue. Twilio's been a growth star since hitting the market at $15 five years ago. It has clocked in with year-over-year revenue growth of at least 40%, and that pace was accelerating. Twilio's top line rose 55% last year, 64% through the first half of this year, and now 65% in its latest report.\nHowever, a good chunk of its recent growth has come from acquisitions, and the 38% in organic revenue growth it just served up for the third quarter could be problematic. The silver lining here is that the stock has fallen so hard since its peak that even the sharply reduced price targets are higher than where Twilio is trading now.\nTelehealth was all the rage during the pandemic. When we couldn't go visit a doctor, therapist, dietician, or other medical specialist, Teladoc was there with its easily accessible and affordable videoconferencing platform.\nTeladoc'sfinancial updateon Wednesday afternoon was a mixed bag. It beat expectations on both ends of the income statement, but like Twilio, its guidance also calls for more red ink than analysts were forecasting. At least 10 analysts would go on to lower their price targets on the stock, but the shares still moved higher on Thursday.\nBusiness is still growing at Teladoc, and the company expects to facilitate more than 14.5 million visits this year. It's standing out despite the growingly competitive marketplace for telehealth.\nThe quarterly report wasn't great, but since the stock has already shed more than half of its value since hitting all-time highs in February, the news came as a relief. Teladoc continues to be ARK Invest's second-largest holding across all of its ETFs, and on Thursday, Wood purchased more shares in four of the funds.\nRobinhood Markets is now a broken IPO, buckling below its $38 debutante price tag after a brutal quarterly report. You can take your pick at which of the numbers tripped up the online-trading platform.\nWe can start with the 35% growth in revenue that was well shy of the 60% growth that Wall Street was expecting. Guidance was also problematic. There was also a sequential dip in monthly active users.\nThe trends aren't kind here. Losses are only getting larger, and average revenue per user is sliding.\nRobinhood Markets traded as high as $85 on its fifth day of trading this summer, and now it's a broken IPO. Wood is buying the dip, but Robinhood Markets is going to have to introduce new features to stand out in an environment where traders are heading elsewhere.","news_type":1,"symbols_score_info":{"ARKIU":0.9,"JE":0.9}},"isVote":1,"tweetType":1,"viewCount":1784,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}